Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease.
Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because diagnosis of aGVHD is exclusively based on clinical symptoms and pathological findings, reliable and noninvasive laboratory tests for accurate diagnosis are required. An activating immunoreceptor, DNAM-1 (CD226), is expressed on T cells and natural killer cells and is involved in the development of aGVHD. Here, we identified a soluble form of DNAM-1 (sDNAM-1) in human sera. In retrospective univariate and multivariate analyses of allo-HSCT patients (n = 71) at a single center, cumulative incidences of all grade (grade I-IV) and sgrade II-IV aGVHD in patients with high maximal serum levels of sDNAM-1 (≥30 pM) in the 7 days before allo-HSCT were significantly higher than those in patients with low maximal serum levels of sDNAM-1 (<30 pM) in the same period. However, sDNAM-1 was not associated with other known allo-HSCT complications. Our data suggest that sDNAM-1 is potentially a unique candidate as a predictive biomarker for the development of aGVHD.
Department of Immunology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.|Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Minoru
M
Kanaya
Department of Immunology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Kazuko
K
Shibuya
Department of Immunology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Rei
R
Hirochika
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Miyoko
M
Kanemoto
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Kazuteru
K
Ohashi
Department of Clinical Trial and Clinical Epidemiology, University of Tsukuba, Ibaraki, Japan.
Masafumi
M
Okada
Department of Clinical Trial and Clinical Epidemiology, University of Tsukuba, Ibaraki, Japan.
Yukiko
Y
Wagatsuma
Department of Immunology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Yukiko
Y
Cho
Department of Clinical Oncology, Ibaraki Prefectural Central Hospital, Ibaraki, Japan.|Ibaraki Clinical Education and Training Center, University of Tsukuba Hospital, Ibaraki, Japan.
Hiroshi
H
Kojima
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Takanori
T
Teshima
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Masahiro
M
Imamura
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Hisashi
H
Sakamaki
Department of Immunology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.|Life Science Center of Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Ibaraki, Japan.|Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), University of Tsukuba, Ibaraki, Japan.
Akira
A
Shibuya
D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome; D000098862:T Lineage-Specific Activation Antigen 1
D000945:Antigens, Differentiation, T-Lymphocyte; D015415:Biomarkers; D000098862:T Lineage-Specific Activation Antigen 1